Publications

" Our main objective is to develop and maintain over time a good expertise and infrastructure ensuring high quality training and clinical research."
Prof Halidou TINTO, PharmD, Msc, PhD Head of the CRUN

2024
Journal Articles
	Ulugbek Khudayberdievich Mirzaev, Serge Ouoba, Ko Ko, Zayar Phyo, Chanroth Chhoung, Akuffo Golda Ataa, Aya Sugiyama, Tomoyuki Akita, Junko Tanaka Systematic review and meta-analysis of hepatitis E seroprevalence in Southeast Asia: a comprehensive assessment of epidemiological patterns Journal Article In: BMC infectious diseases, vol. 24, iss. 1, 2024, ISSN: 1471-2334. Abstract \| BibTeX \| Tags: Asia, doi:10.1186/s12879-024-09349-2, Female, Hepatitis Antibodies* / blood, Hepatitis E virus* / immunology, Hepatitis E* / blood, Hepatitis E* / epidemiology, Humans, Immunoglobulin G* / blood, Immunoglobulin M* / blood, Junko Tanaka, Male, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11127338, pmid:38789918, Pregnancy, Prevalence, PubMed Abstract, Risk Factors, Serge Ouoba, Seroepidemiologic Studies, Southeastern / epidemiology, Systematic review, Ulugbek Khudayberdievich Mirzaev \| Links: Close Close @article{Mirzaev2024, title = {Systematic review and meta-analysis of hepatitis E seroprevalence in Southeast Asia: a comprehensive assessment of epidemiological patterns}, author = {Ulugbek Khudayberdievich Mirzaev and Serge Ouoba and Ko Ko and Zayar Phyo and Chanroth Chhoung and Akuffo Golda Ataa and Aya Sugiyama and Tomoyuki Akita and Junko Tanaka}, url = {https://pubmed.ncbi.nlm.nih.gov/38789918/}, doi = {10.1186/S12879-024-09349-2}, issn = {1471-2334}, year = {2024}, date = {2024-01-01}, journal = {BMC infectious diseases}, volume = {24}, issue = {1}, publisher = {BMC Infect Dis}, abstract = {The burden of hepatitis E in Southeast Asia is substantial, influenced by its distinct socio-economic and environmental factors, as well as variations in healthcare systems. The aim of this study was to assess the pooled seroprevalence of hepatitis E across countries within the Southeast Asian region by the UN division. The study analyzed 66 papers across PubMed, Web of Science, and Scopus databases, encompassing data from of 44,850 individuals focusing on anti-HEV seroprevalence. The investigation spanned nine countries, excluding Brunei and East Timor due to lack of data. The pooled prevalence of anti-HEV IgG was determined to be 21.03%, with the highest prevalence observed in Myanmar (33.46%) and the lowest in Malaysia (5.93%). IgM prevalence was highest in Indonesia (12.43%) and lowest in Malaysia (0.91%). The study stratified populations into high-risk (farm workers, chronic patients) and low-risk groups (general population, blood donors, pregnant women, hospital patients). It revealed a higher IgG\textemdash28.9%, IgM\textemdash4.42% prevalence in the former group, while the latter group exhibited figures of 17.86% and 3.15%, respectively, indicating occupational and health-related vulnerabilities to HEV. A temporal analysis (1987\textendash2023), indicated an upward trend in both IgG and IgM prevalence, suggesting an escalating HEV burden. These findings contribute to a better understanding of HEV seroprevalence in Southeast Asia, shedding light on important public health implications and suggesting directions for further research and intervention strategies. Key points Research Question Investigate the seroprevalence of hepatitis E virus (HEV) in Southeast Asian countries focusing on different patterns, timelines, and population cohorts. Findings Sporadic Transmission of IgG and IgM Prevalence: • Pooled anti-HEV IgG prevalence: 21.03% • Pooled anti-HEV IgM prevalence: 3.49% Seroprevalence among specific groups: High-risk group (farm workers and chronic patients): • anti-HEV IgG: 28.9% • anti-HEV IgM: 4.42% Low-risk group (general population, blood donors, pregnant women, hospital patients): • anti-HEV IgG: 17.86% • anti-HEV IgM: 3.15% Temporal Seroprevalence of HEV: Anti-HEV IgG prevalence increased over decades (1987\textendash1999; 2000\textendash2010; 2011\textendash2023): 12.47%, 18.43%, 29.17% as an anti-HEV IgM prevalence: 1.92%, 2.44%, 5.27% Importance Provides a comprehensive overview of HEV seroprevalence in Southeast Asia. Highlights variation in seroprevalence among different population groups. Reveals increasing trend in HEV seroprevalence over the years. Distinguishes between sporadic and epidemic cases for a better understanding of transmission dynamics.}, keywords = {Asia, doi:10.1186/s12879-024-09349-2, Female, Hepatitis Antibodies* / blood, Hepatitis E virus* / immunology, Hepatitis E* / blood, Hepatitis E* / epidemiology, Humans, Immunoglobulin G* / blood, Immunoglobulin M* / blood, Junko Tanaka, Male, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11127338, pmid:38789918, Pregnancy, Prevalence, PubMed Abstract, Risk Factors, Serge Ouoba, Seroepidemiologic Studies, Southeastern / epidemiology, Systematic review, Ulugbek Khudayberdievich Mirzaev}, pubstate = {published}, tppubtype = {article} } Close The burden of hepatitis E in Southeast Asia is substantial, influenced by its distinct socio-economic and environmental factors, as well as variations in healthcare systems. The aim of this study was to assess the pooled seroprevalence of hepatitis E across countries within the Southeast Asian region by the UN division. The study analyzed 66 papers across PubMed, Web of Science, and Scopus databases, encompassing data from of 44,850 individuals focusing on anti-HEV seroprevalence. The investigation spanned nine countries, excluding Brunei and East Timor due to lack of data. The pooled prevalence of anti-HEV IgG was determined to be 21.03%, with the highest prevalence observed in Myanmar (33.46%) and the lowest in Malaysia (5.93%). IgM prevalence was highest in Indonesia (12.43%) and lowest in Malaysia (0.91%). The study stratified populations into high-risk (farm workers, chronic patients) and low-risk groups (general population, blood donors, pregnant women, hospital patients). It revealed a higher IgG—28.9%, IgM—4.42% prevalence in the former group, while the latter group exhibited figures of 17.86% and 3.15%, respectively, indicating occupational and health-related vulnerabilities to HEV. A temporal analysis (1987–2023), indicated an upward trend in both IgG and IgM prevalence, suggesting an escalating HEV burden. These findings contribute to a better understanding of HEV seroprevalence in Southeast Asia, shedding light on important public health implications and suggesting directions for further research and intervention strategies. Key points Research Question Investigate the seroprevalence of hepatitis E virus (HEV) in Southeast Asian countries focusing on different patterns, timelines, and population cohorts. Findings Sporadic Transmission of IgG and IgM Prevalence: • Pooled anti-HEV IgG prevalence: 21.03% • Pooled anti-HEV IgM prevalence: 3.49% Seroprevalence among specific groups: High-risk group (farm workers and chronic patients): • anti-HEV IgG: 28.9% • anti-HEV IgM: 4.42% Low-risk group (general population, blood donors, pregnant women, hospital patients): • anti-HEV IgG: 17.86% • anti-HEV IgM: 3.15% Temporal Seroprevalence of HEV: Anti-HEV IgG prevalence increased over decades (1987–1999; 2000–2010; 2011–2023): 12.47%, 18.43%, 29.17% as an anti-HEV IgM prevalence: 1.92%, 2.44%, 5.27% Importance Provides a comprehensive overview of HEV seroprevalence in Southeast Asia. Highlights variation in seroprevalence among different population groups. Reveals increasing trend in HEV seroprevalence over the years. Distinguishes between sporadic and epidemic cases for a better understanding of transmission dynamics. Close
	Golda Ataa Akuffo, Serge Ouoba, Ko Ko, Chanroth Chhoung, Zayar Phyo, Ulugbek Khudayberdievich Mirzaev, Aya Sugiyama, Tomoyuki Akita, Junko Tanaka Assessing the diagnostic accuracy of serological tests for hepatitis delta virus diagnosis: a systematic review and meta-analysis Journal Article In: Scientific reports, vol. 14, iss. 1, 2024, ISSN: 2045-2322. Abstract \| BibTeX \| Tags: doi:10.1038/s41598-024-69304-8, Golda Ataa Akuffo, Hepatitis Antibodies / blood, Hepatitis D* / blood, Hepatitis D* / diagnosis, Hepatitis D* / immunology, Hepatitis D* / virology, Hepatitis Delta Virus* / immunology, Humans, Immunoglobulin G / blood, Immunoglobulin M / blood, Junko Tanaka, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11316141, pmid:39122751, PubMed Abstract, Sensitivity and Specificity, Serge Ouoba, Serologic Tests / methods, Serologic Tests* / standards, Systematic review \| Links: Close Close @article{Akuffo2024, title = {Assessing the diagnostic accuracy of serological tests for hepatitis delta virus diagnosis: a systematic review and meta-analysis}, author = {Golda Ataa Akuffo and Serge Ouoba and Ko Ko and Chanroth Chhoung and Zayar Phyo and Ulugbek Khudayberdievich Mirzaev and Aya Sugiyama and Tomoyuki Akita and Junko Tanaka}, url = {https://pubmed.ncbi.nlm.nih.gov/39122751/}, doi = {10.1038/S41598-024-69304-8}, issn = {2045-2322}, year = {2024}, date = {2024-01-01}, journal = {Scientific reports}, volume = {14}, issue = {1}, publisher = {Sci Rep}, abstract = {Hepatitis Delta Virus (HDV), a satellite virus of Hepatitis B virus, exacerbates liver damage in affected individuals. Screening for HDV antibodies in HBsAg positive patients is recommended, but the diagnostic accuracy of serological tests remains uncertain. This review aimed to assess the diagnostic accuracy of serological tests for HDV. We searched PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Scopus etc. for relevant studies. Studies measuring the sensitivity and specificity of serological HDV tests against PCR as a reference standard were included. Pooled sensitivity and specificity for each test method and sero-marker were calculated. The review included six studies with 11 study arms, evaluating ARCHITECT immunoassay, EIA, ELISA, QMAC, RIA, and Western Blot test methods targeting Anti-HDV IgG, Total anti-HDV and Anti-HDV IgM. Sensitivities for Anti-HDV IgG, Total Anti-HDV and Anti-HDV IgM, tests were 97.4%, 51.9%, and 62.0%, respectively, with specificities of 95.3%, 80.0%, and 85.0%. Our findings, with its limited number of studies, suggest that HDV serological tests, particularly those identifying Anti IgG exhibit high accuracy and can serve as effective screening tools for HDV.}, keywords = {doi:10.1038/s41598-024-69304-8, Golda Ataa Akuffo, Hepatitis Antibodies / blood, Hepatitis D* / blood, Hepatitis D* / diagnosis, Hepatitis D* / immunology, Hepatitis D* / virology, Hepatitis Delta Virus* / immunology, Humans, Immunoglobulin G / blood, Immunoglobulin M / blood, Junko Tanaka, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11316141, pmid:39122751, PubMed Abstract, Sensitivity and Specificity, Serge Ouoba, Serologic Tests / methods, Serologic Tests* / standards, Systematic review}, pubstate = {published}, tppubtype = {article} } Close Hepatitis Delta Virus (HDV), a satellite virus of Hepatitis B virus, exacerbates liver damage in affected individuals. Screening for HDV antibodies in HBsAg positive patients is recommended, but the diagnostic accuracy of serological tests remains uncertain. This review aimed to assess the diagnostic accuracy of serological tests for HDV. We searched PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Scopus etc. for relevant studies. Studies measuring the sensitivity and specificity of serological HDV tests against PCR as a reference standard were included. Pooled sensitivity and specificity for each test method and sero-marker were calculated. The review included six studies with 11 study arms, evaluating ARCHITECT immunoassay, EIA, ELISA, QMAC, RIA, and Western Blot test methods targeting Anti-HDV IgG, Total anti-HDV and Anti-HDV IgM. Sensitivities for Anti-HDV IgG, Total Anti-HDV and Anti-HDV IgM, tests were 97.4%, 51.9%, and 62.0%, respectively, with specificities of 95.3%, 80.0%, and 85.0%. Our findings, with its limited number of studies, suggest that HDV serological tests, particularly those identifying Anti IgG exhibit high accuracy and can serve as effective screening tools for HDV. Close
	Zayar Phyo, Ko Ko, Serge Ouoba, Aya Sugiyama, Ulugbek Khudayberdievich Mirzaev, Golda Ataa Akuffo, Chanroth Chhoung, Tomoyuki Akita, Junko Tanaka Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis Journal Article In: PloS one, vol. 19, iss. 9, 2024, ISSN: 1932-6203. Abstract \| BibTeX \| Tags: doi:10.1371/journal.pone.0307872, Endemic Diseases, Genotype, Hepacivirus / genetics, Hepacivirus* / isolation & purification, Hepatitis C* / epidemiology, Hepatitis C* / virology, Humans, Junko Tanaka, Ko Ko, MEDLINE, Meta-Analysis, Myanmar / epidemiology, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11412534, pmid:39298388, Prevalence, PubMed Abstract, RNA, Seroepidemiologic Studies, Systematic review, Viral / genetics, Zayar Phyo \| Links: Close Close @article{Phyo2024, title = {Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis}, author = {Zayar Phyo and Ko Ko and Serge Ouoba and Aya Sugiyama and Ulugbek Khudayberdievich Mirzaev and Golda Ataa Akuffo and Chanroth Chhoung and Tomoyuki Akita and Junko Tanaka}, url = {https://pubmed.ncbi.nlm.nih.gov/39298388/}, doi = {10.1371/JOURNAL.PONE.0307872}, issn = {1932-6203}, year = {2024}, date = {2024-01-01}, journal = {PloS one}, volume = {19}, issue = {9}, publisher = {PLoS One}, abstract = {Background Comprehensive details on Hepatitis C virus (HCV) infection in Myanmar are lacking. This study determined the prevalence of HCV antibodies and ribonucleic acid (RNA) and the distribution of HCV genotypes across different populations in Myanmar from 1990 to 2023. Material and methods A systematic search in PubMed, Web of Science, Scopus, and local journals identified studies reporting on HCV antibodies, RNA, and genotypes, excluding clinical research related to liver disease prognosis. Screening and data extraction was done by two authors and study populations were categorized into low-risk, high-risk, liver disease patients, and refugees outside the country. The pooled prevalence was performed by Dersimonian and Laird method using the R program. The publication bias was shown by funnel plot, the Egger test was used to assess the symmetry of the plot, and the heterogeneity was examined by the Cochran Q test and I2 index. Results Out of 135 reports screened for eligibility, 35 reports comprising 51 studies were included in which 33 studies provided data on HCV seroprevalence in 685,403 individuals, 8 studies reported HCV RNA prevalence in 25,018 individuals, and 10 studies examined HCV genotypes in 1,845 individuals. The pooled seroprevalence of HCV among low-risk, high-risk, liver disease patients and refugees were 2.18%, 37.07%, 33.84%, and 2.52% respectively. HCV RNA-positive rates in these groups were 1.40%, 5.25%, 24.96%, and 0.84% respectively. Seroprevalence studies showed publication bias (Egger test}, keywords = {doi:10.1371/journal.pone.0307872, Endemic Diseases, Genotype, Hepacivirus / genetics, Hepacivirus* / isolation \& purification, Hepatitis C* / epidemiology, Hepatitis C* / virology, Humans, Junko Tanaka, Ko Ko, MEDLINE, Meta-Analysis, Myanmar / epidemiology, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11412534, pmid:39298388, Prevalence, PubMed Abstract, RNA, Seroepidemiologic Studies, Systematic review, Viral / genetics, Zayar Phyo}, pubstate = {published}, tppubtype = {article} } Close Background Comprehensive details on Hepatitis C virus (HCV) infection in Myanmar are lacking. This study determined the prevalence of HCV antibodies and ribonucleic acid (RNA) and the distribution of HCV genotypes across different populations in Myanmar from 1990 to 2023. Material and methods A systematic search in PubMed, Web of Science, Scopus, and local journals identified studies reporting on HCV antibodies, RNA, and genotypes, excluding clinical research related to liver disease prognosis. Screening and data extraction was done by two authors and study populations were categorized into low-risk, high-risk, liver disease patients, and refugees outside the country. The pooled prevalence was performed by Dersimonian and Laird method using the R program. The publication bias was shown by funnel plot, the Egger test was used to assess the symmetry of the plot, and the heterogeneity was examined by the Cochran Q test and I2 index. Results Out of 135 reports screened for eligibility, 35 reports comprising 51 studies were included in which 33 studies provided data on HCV seroprevalence in 685,403 individuals, 8 studies reported HCV RNA prevalence in 25,018 individuals, and 10 studies examined HCV genotypes in 1,845 individuals. The pooled seroprevalence of HCV among low-risk, high-risk, liver disease patients and refugees were 2.18%, 37.07%, 33.84%, and 2.52% respectively. HCV RNA-positive rates in these groups were 1.40%, 5.25%, 24.96%, and 0.84% respectively. Seroprevalence studies showed publication bias (Egger test Close
2023
Journal Articles
	Anna Maria Eijk, Kasia Stepniewska, Jenny Hill, Steve M. Taylor, Stephen J. Rogerson, Gilles Cottrell, R. Matthew Chico, Julie R. Gutman, Halidou Tinto, Holger W. Unger, Stephanie K. Yanow, Steven R. Meshnick, Feiko O. Kuile, Alfredo Mayor, Steve M. Taylor, Stephen J. Rogerson, R. Matthew Chico, Julie R. Gutman, Hallidou Tinto, Holger W. Unger, Stephanie K. Yanow, Manfred Accrombessi, Ayola A. Adegnika, Rukhsana Ahmed, Eliana María Arango-Flórez, Myriam Arevalo-Herrera, Emmanual Arinaitwe, Paulo Arnaldo, Per Ashorn, Ulla Ashorn, Azucena Bardaji, Inoni Betuela, Praveen K. Bharti, Francis Bohissou, Camila Bôtto-Menezes, Vera Braun, Valerie Briand, Jessica Briggs, María Eugenia Castellanos, Daniel Chandramohan, Enesia Banda Chaponda, Chetan Chitnis, Lauren M. Cohee, Michel Cot, Umberto d'Alessandro, Lise Denoeud-Ndam, Meghna Desai, Alassane Dicko, Xavier Ding, Grant Dorsey, Patrick E. Duffy, Maha A. Elbadry, Sonia M. Enosse, Yue Fan, Nadine Fievet, Michal Fried, Blaise Genton, Raquel Gonzalez, Brian Greenwood, Linda Kalilani, Johanna H. Kattenberg, Kassoum Kayentao, Carole Khairallah, Christopher L. King, Dhanpat Kumar Kochar, Swati Kochar, Felix Koukouikila-Koussounda, Sarah H. Landis, Miriam K. Laufer, Rose F. Leke, Eusebio Macete, Sonia Maculuve, Mwayiwawo Madanitsa, Almahamoudou Mahamar, Ken Maleta, Indu Malhotra, Rella Zoleko Manego, Flor Ernestina Martinez-Espinosa, Achille Massougbodji, Don Mathanga, Michela Menegon, Clara Menendez, Petra Mens, Martin Meremikwu, Frank P. Mockenhaupt, Ghyslain Mombo-Ngoma, Dominic Mosha, Ivo Mueller, Alain Nahum, Paul Natureeba, Nicaise Ndam, Francine Ntoumi, Olabisi A. Oduwole, Bernard A. Okech, Maria Ome-Kaius, Kephas Otieno, Norma Padilla, Michal Ramharter, Rosemary Rochford, Anna Rosanas-Urgell, Maria Ruperez, Katherine R. Sabourin, Sergi Sanz, Henk D. Schallig, Susana Scott, Esperanca Sevene, Carlo Severini, Harry Tagbor, Diane Wallace Taylor, Maminata Traore Coulibaly, Ana Vasquez, Annie Walker-Abbey, Blair J. Wylie, Djimon M. Zannou, Stephen R. Meshnick Prevalence of and risk factors for microscopic and submicroscopic malaria infections in pregnancy: a systematic review and meta-analysis Journal Article In: The Lancet. Global health, vol. 11, iss. 7, pp. e1061-e1074, 2023, ISSN: 2214-109X. Abstract \| BibTeX \| Tags: {Adult, Anna Maria van Eijk, Antimalarials* / therapeutic use, Author(firstnames='Achille', Author(firstnames='Alain', Author(firstnames='Alassane', Author(firstnames='Alfredo', Author(firstnames='Almahamoudou', Author(firstnames='Ana', Author(firstnames='Anna', Author(firstnames='Annie', Author(firstnames='Ayola A', Author(firstnames='Azucena', Author(firstnames='Bernard A', Author(firstnames='Blair J', Author(firstnames='Blaise', Author(firstnames='Brian', Author(firstnames='Camila', Author(firstnames='Carlo', Author(firstnames='Carole', Author(firstnames='Chetan', Author(firstnames='Christopher L', Author(firstnames='Clara', Author(firstnames='Daniel', Author(firstnames='Dhanpat Kumar', Author(firstnames='Diane Wallace', Author(firstnames='Djimon M', Author(firstnames='Dominic', Author(firstnames='Don', Author(firstnames='Eliana María', Author(firstnames='Emmanual', Author(firstnames='Enesia Banda', Author(firstnames='Esperanca', Author(firstnames='Eusebio', Author(firstnames='Feiko O', Author(firstnames='Felix', Author(firstnames='Flor Ernestina', Author(firstnames='Francine', Author(firstnames='Francis', Author(firstnames='Frank P', Author(firstnames='Ghyslain', Author(firstnames='Gilles', Author(firstnames='Grant', Author(firstnames='Hallidou', Author(firstnames='Harry', Author(firstnames='Henk D', Author(firstnames='Holger W', Author(firstnames='Indu', Author(firstnames='Inoni', Author(firstnames='Ivo', Author(firstnames='Jenny', Author(firstnames='Jessica', Author(firstnames='Johanna H', Author(firstnames='Julie R', Author(firstnames='Kasia', Author(firstnames='Kassoum', Author(firstnames='Katherine R', Author(firstnames='Ken', Author(firstnames='Kephas', Author(firstnames='Lauren M', Author(firstnames='Linda', Author(firstnames='Lise', Author(firstnames='Maha A', Author(firstnames='Maminata', Author(firstnames='Manfred', Author(firstnames='María Eugenia', Author(firstnames='Maria', Author(firstnames='Martin', Author(firstnames='Meghna', Author(firstnames='Michal', Author(firstnames='Michel', Author(firstnames='Michela', Author(firstnames='Miriam K', Author(firstnames='Mwayiwawo', Author(firstnames='Myriam', Author(firstnames='Nadine', Author(firstnames='Nicaise', Author(firstnames='Norma', Author(firstnames='Olabisi A', Author(firstnames='Patrick E', Author(firstnames='Paul', Author(firstnames='Paulo', Author(firstnames='Per', Author(firstnames='Petra', Author(firstnames='Praveen K', Author(firstnames='R Matthew', Author(firstnames='Raquel', Author(firstnames='Rella', Author(firstnames='Rose F', Author(firstnames='Rosemary', Author(firstnames='Rukhsana', Author(firstnames='Sarah H', Author(firstnames='Sergi', Author(firstnames='Sonia M', Author(firstnames='Sonia', Author(firstnames='Stephanie K', Author(firstnames='Stephen J', Author(firstnames='Stephen R', Author(firstnames='Steve M', Author(firstnames='Susana', Author(firstnames='Swati', Author(firstnames='Ulla', Author(firstnames='Umberto', Author(firstnames='Valerie', Author(firstnames='Vera', Author(firstnames='Xavier', Author(firstnames='Yue', CollabAuthor(name='Subpatent Malaria in Pregnancy Group', Falciparum* / drug therapy, Female, Humans, Kasia Stepniewska, Malaria, Malaria* / prevention & control, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Non-U.S. Gov't, P.H.S., PMC10880462, Pregnancy, Prevalence, PubMed Abstract, Research Support, Risk Factors, Systematic review, U.S. Gov't \| Links: Close Close @article{nokey, title = {Prevalence of and risk factors for microscopic and submicroscopic malaria infections in pregnancy: a systematic review and meta-analysis}, author = {Anna Maria Eijk and Kasia Stepniewska and Jenny Hill and Steve M. Taylor and Stephen J. Rogerson and Gilles Cottrell and R. Matthew Chico and Julie R. Gutman and Halidou Tinto and Holger W. Unger and Stephanie K. Yanow and Steven R. Meshnick and Feiko O. Kuile and Alfredo Mayor and Steve M. Taylor and Stephen J. Rogerson and R. Matthew Chico and Julie R. Gutman and Hallidou Tinto and Holger W. Unger and Stephanie K. Yanow and Manfred Accrombessi and Ayola A. Adegnika and Rukhsana Ahmed and Eliana Mar\'{i}a Arango-Fl\'{o}rez and Myriam Arevalo-Herrera and Emmanual Arinaitwe and Paulo Arnaldo and Per Ashorn and Ulla Ashorn and Azucena Bardaji and Inoni Betuela and Praveen K. Bharti and Francis Bohissou and Camila B\^{o}tto-Menezes and Vera Braun and Valerie Briand and Jessica Briggs and Mar\'{i}a Eugenia Castellanos and Daniel Chandramohan and Enesia Banda Chaponda and Chetan Chitnis and Lauren M. Cohee and Michel Cot and Umberto d'Alessandro and Lise Denoeud-Ndam and Meghna Desai and Alassane Dicko and Xavier Ding and Grant Dorsey and Patrick E. Duffy and Maha A. Elbadry and Sonia M. Enosse and Yue Fan and Nadine Fievet and Michal Fried and Blaise Genton and Raquel Gonzalez and Brian Greenwood and Linda Kalilani and Johanna H. Kattenberg and Kassoum Kayentao and Carole Khairallah and Christopher L. King and Dhanpat Kumar Kochar and Swati Kochar and Felix Koukouikila-Koussounda and Sarah H. Landis and Miriam K. Laufer and Rose F. Leke and Eusebio Macete and Sonia Maculuve and Mwayiwawo Madanitsa and Almahamoudou Mahamar and Ken Maleta and Indu Malhotra and Rella Zoleko Manego and Flor Ernestina Martinez-Espinosa and Achille Massougbodji and Don Mathanga and Michela Menegon and Clara Menendez and Petra Mens and Martin Meremikwu and Frank P. Mockenhaupt and Ghyslain Mombo-Ngoma and Dominic Mosha and Ivo Mueller and Alain Nahum and Paul Natureeba and Nicaise Ndam and Francine Ntoumi and Olabisi A. Oduwole and Bernard A. Okech and Maria Ome-Kaius and Kephas Otieno and Norma Padilla and Michal Ramharter and Rosemary Rochford and Anna Rosanas-Urgell and Maria Ruperez and Katherine R. Sabourin and Sergi Sanz and Henk D. Schallig and Susana Scott and Esperanca Sevene and Carlo Severini and Harry Tagbor and Diane Wallace Taylor and Maminata Traore Coulibaly and Ana Vasquez and Annie Walker-Abbey and Blair J. Wylie and Djimon M. Zannou and Stephen R. Meshnick}, url = {https://pubmed.ncbi.nlm.nih.gov/37276878/}, doi = {10.1016/S2214-109X(23)00194-8}, issn = {2214-109X}, year = {2023}, date = {2023-01-01}, journal = {The Lancet. Global health}, volume = {11}, issue = {7}, pages = {e1061-e1074}, publisher = {Lancet Glob Health}, abstract = {Background: Malaria infections during pregnancy can cause adverse birth outcomes, yet many infections are undetected by microscopy. We aimed to describe the epidemiology of submicroscopic malaria infections in pregnant women in Asia, the Americas, and Africa using aggregated and individual participant data (IPD). Methods: For this systematic review and meta-analysis, studies (published Jan 1, 1997 to Nov 10, 2021) with information on both microscopic and submicroscopic infections during pregnancy from Asia, the Americas, or Africa, identified in the Malaria-in-Pregnancy Library, were eligible. Studies (or subgroups or study groups) that selected participants on the basis of the presence of fever or a positive blood smear were excluded to avoid selection bias. We obtained IPD (when available) and aggregated data. Estimates of malaria transmission intensity and sulfadoxine\textendashpyrimethamine resistance, matched by study location and year, were obtained using publicly available data. One-stage multivariable logit and multinomial models with random intercepts for study site were used in meta-analysis to assess prevalence of and risk factors for submicroscopic infections during pregnancy and at delivery. This study is registered with PROSPERO, number CRD42015027342. Findings: The search identified 87 eligible studies, 68 (78%) of which contributed to the analyses. Of these 68 studies, 45 (66%) studies contributed IPD (48 869 participants) and 23 (34%) studies contributed aggregated data (11 863 participants). During pregnancy, median prevalence estimates were 13·5% (range 0·0\textendash55·9, 66 substudies) for submicroscopic and 8·0% (0·0\textendash50·6, 66 substudies) for microscopic malaria. Among women with positive Plasmodium nucleic acid amplification tests (NAATs), the median proportion of submicroscopic infections was 58·7% (range 0·0\textendash100); this proportion was highest in the Americas (73·3%, 0·0\textendash100), followed by Asia (67·2%, 36·4\textendash100) and Africa (56·5%, 20·5\textendash97·7). In individual patient data analysis, compared with women with no malaria infections, those with submicroscopic infections were more likely to present with fever in Africa (adjusted odds ratio 1·32, 95% CI 1·02\textendash1·72; p=0·038) but not in other regions. Among women with NAAT-positive infections in Asia and the Americas, Plasmodium vivax infections were more likely to be submicroscopic than Plasmodium falciparum infections (3·69, 2·45\textendash5·54; p\<0·0001). Risk factors for submicroscopic infections among women with NAAT-positive infections in Africa included older age (age ≥30 years), multigravidity, and no HIV infection. Interpretation: During pregnancy, submicroscopic infections are more common than microscopic infections and are associated with fever in Africa. Malaria control in pregnancy should target both microscopic and submicroscopic infections. Funding: Bill \& Melinda Gates Foundation through the Worldwide Antimalarial Resistance Network.}, keywords = {{Adult, Anna Maria van Eijk, Antimalarials* / therapeutic use, Author(firstnames='Achille', Author(firstnames='Alain', Author(firstnames='Alassane', Author(firstnames='Alfredo', Author(firstnames='Almahamoudou', Author(firstnames='Ana', Author(firstnames='Anna', Author(firstnames='Annie', Author(firstnames='Ayola A', Author(firstnames='Azucena', Author(firstnames='Bernard A', Author(firstnames='Blair J', Author(firstnames='Blaise', Author(firstnames='Brian', Author(firstnames='Camila', Author(firstnames='Carlo', Author(firstnames='Carole', Author(firstnames='Chetan', Author(firstnames='Christopher L', Author(firstnames='Clara', Author(firstnames='Daniel', Author(firstnames='Dhanpat Kumar', Author(firstnames='Diane Wallace', Author(firstnames='Djimon M', Author(firstnames='Dominic', Author(firstnames='Don', Author(firstnames='Eliana Mar\'{i}a', Author(firstnames='Emmanual', Author(firstnames='Enesia Banda', Author(firstnames='Esperanca', Author(firstnames='Eusebio', Author(firstnames='Feiko O', Author(firstnames='Felix', Author(firstnames='Flor Ernestina', Author(firstnames='Francine', Author(firstnames='Francis', Author(firstnames='Frank P', Author(firstnames='Ghyslain', Author(firstnames='Gilles', Author(firstnames='Grant', Author(firstnames='Hallidou', Author(firstnames='Harry', Author(firstnames='Henk D', Author(firstnames='Holger W', Author(firstnames='Indu', Author(firstnames='Inoni', Author(firstnames='Ivo', Author(firstnames='Jenny', Author(firstnames='Jessica', Author(firstnames='Johanna H', Author(firstnames='Julie R', Author(firstnames='Kasia', Author(firstnames='Kassoum', Author(firstnames='Katherine R', Author(firstnames='Ken', Author(firstnames='Kephas', Author(firstnames='Lauren M', Author(firstnames='Linda', Author(firstnames='Lise', Author(firstnames='Maha A', Author(firstnames='Maminata', Author(firstnames='Manfred', Author(firstnames='Mar\'{i}a Eugenia', Author(firstnames='Maria', Author(firstnames='Martin', Author(firstnames='Meghna', Author(firstnames='Michal', Author(firstnames='Michel', Author(firstnames='Michela', Author(firstnames='Miriam K', Author(firstnames='Mwayiwawo', Author(firstnames='Myriam', Author(firstnames='Nadine', Author(firstnames='Nicaise', Author(firstnames='Norma', Author(firstnames='Olabisi A', Author(firstnames='Patrick E', Author(firstnames='Paul', Author(firstnames='Paulo', Author(firstnames='Per', Author(firstnames='Petra', Author(firstnames='Praveen K', Author(firstnames='R Matthew', Author(firstnames='Raquel', Author(firstnames='Rella', Author(firstnames='Rose F', Author(firstnames='Rosemary', Author(firstnames='Rukhsana', Author(firstnames='Sarah H', Author(firstnames='Sergi', Author(firstnames='Sonia M', Author(firstnames='Sonia', Author(firstnames='Stephanie K', Author(firstnames='Stephen J', Author(firstnames='Stephen R', Author(firstnames='Steve M', Author(firstnames='Susana', Author(firstnames='Swati', Author(firstnames='Ulla', Author(firstnames='Umberto', Author(firstnames='Valerie', Author(firstnames='Vera', Author(firstnames='Xavier', Author(firstnames='Yue', CollabAuthor(name='Subpatent Malaria in Pregnancy Group', Falciparum* / drug therapy, Female, Humans, Kasia Stepniewska, Malaria, Malaria* / prevention \& control, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Non-U.S. Gov't, P.H.S., PMC10880462, Pregnancy, Prevalence, PubMed Abstract, Research Support, Risk Factors, Systematic review, U.S. Gov't}, pubstate = {published}, tppubtype = {article} } Close Background: Malaria infections during pregnancy can cause adverse birth outcomes, yet many infections are undetected by microscopy. We aimed to describe the epidemiology of submicroscopic malaria infections in pregnant women in Asia, the Americas, and Africa using aggregated and individual participant data (IPD). Methods: For this systematic review and meta-analysis, studies (published Jan 1, 1997 to Nov 10, 2021) with information on both microscopic and submicroscopic infections during pregnancy from Asia, the Americas, or Africa, identified in the Malaria-in-Pregnancy Library, were eligible. Studies (or subgroups or study groups) that selected participants on the basis of the presence of fever or a positive blood smear were excluded to avoid selection bias. We obtained IPD (when available) and aggregated data. Estimates of malaria transmission intensity and sulfadoxine–pyrimethamine resistance, matched by study location and year, were obtained using publicly available data. One-stage multivariable logit and multinomial models with random intercepts for study site were used in meta-analysis to assess prevalence of and risk factors for submicroscopic infections during pregnancy and at delivery. This study is registered with PROSPERO, number CRD42015027342. Findings: The search identified 87 eligible studies, 68 (78%) of which contributed to the analyses. Of these 68 studies, 45 (66%) studies contributed IPD (48 869 participants) and 23 (34%) studies contributed aggregated data (11 863 participants). During pregnancy, median prevalence estimates were 13·5% (range 0·0–55·9, 66 substudies) for submicroscopic and 8·0% (0·0–50·6, 66 substudies) for microscopic malaria. Among women with positive Plasmodium nucleic acid amplification tests (NAATs), the median proportion of submicroscopic infections was 58·7% (range 0·0–100); this proportion was highest in the Americas (73·3%, 0·0–100), followed by Asia (67·2%, 36·4–100) and Africa (56·5%, 20·5–97·7). In individual patient data analysis, compared with women with no malaria infections, those with submicroscopic infections were more likely to present with fever in Africa (adjusted odds ratio 1·32, 95% CI 1·02–1·72; p=0·038) but not in other regions. Among women with NAAT-positive infections in Asia and the Americas, Plasmodium vivax infections were more likely to be submicroscopic than Plasmodium falciparum infections (3·69, 2·45–5·54; p<0·0001). Risk factors for submicroscopic infections among women with NAAT-positive infections in Africa included older age (age ≥30 years), multigravidity, and no HIV infection. Interpretation: During pregnancy, submicroscopic infections are more common than microscopic infections and are associated with fever in Africa. Malaria control in pregnancy should target both microscopic and submicroscopic infections. Funding: Bill & Melinda Gates Foundation through the Worldwide Antimalarial Resistance Network. Close
	Isidore W. Yerbanga, Seydou Nakanabo Diallo, Toussaint Rouamba, Agustin Resendiz-Sharpe, Katrien Lagrou, Olivier Denis, Hector Rodriguez-Villalobos, Isabel Montesinos, Sanata Bamba Performances of disk diffusion method for determining triazole susceptibility of Aspergillus species: Systematic review Journal Article In: Journal de mycologie medicale, vol. 33, iss. 4, 2023, ISSN: 1773-0449. Abstract \| BibTeX \| Tags: Agar, Antifungal Agents* / pharmacology, Aspergillus, doi:10.1016/j.mycmed.2023.101413, Isidore W Yerbanga, Itraconazole* / pharmacology, MEDLINE, Microbial Sensitivity Tests, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, pmid:37603962, PubMed Abstract, Reproducibility of Results, Review, Sanata Bamba, Seydou Nakanabo Diallo, Systematic review, Triazoles / pharmacology, Voriconazole / pharmacology \| Links: Close Close @article{Yerbanga2023, title = {Performances of disk diffusion method for determining triazole susceptibility of Aspergillus species: Systematic review}, author = {Isidore W. Yerbanga and Seydou Nakanabo Diallo and Toussaint Rouamba and Agustin Resendiz-Sharpe and Katrien Lagrou and Olivier Denis and Hector Rodriguez-Villalobos and Isabel Montesinos and Sanata Bamba}, url = {https://pubmed.ncbi.nlm.nih.gov/37603962/}, doi = {10.1016/J.MYCMED.2023.101413}, issn = {1773-0449}, year = {2023}, date = {2023-01-01}, journal = {Journal de mycologie medicale}, volume = {33}, issue = {4}, publisher = {J Mycol Med}, abstract = {The therapeutic management of invasive aspergillosis should be guided by antifungal susceptibility testing (AFST). The disk diffusion (DD) method due to its simplicity and low cost could be an appropriate alternative to the reference methods (CLSI, EUCAST) which are not suitable for AFST in routine clinical microbiology laboratories, particularly in resource-constrained settings. This review summarizes the available data on the performance of the DD method in determining triazole susceptibility profile of Aspergillus species. The published articles on the performance of DD method for determining triazole susceptibility of Aspergillus spp. were systematically searched on major medical databases and Google Scholar. We identified 2725 articles of which 13 met the inclusion criteria. The overall average agreement value obtained between DD and CLSI broth microdilution (CLSI-BMD) methods for the itraconazole 10 µg disk (70.75%) was low especially when the medium used was not Mueller-Hinton (MH) agar. In contrast average agreement for the voriconazole 1 µg disk and the posaconazole 5 µg disk were \> 94% regardless of media used. The correlation coefficient values between the DD and CLSI-BMD methods on MH agar were acceptable (≥ 0.71) for the itraconazole 10 µg disk and posaconazole 5 µg disk and good (≥ 0.80) for the voriconazole 1 and 10 µg disk. The reproducibility of the DD method regardless to the medium used was ≥ 82%. This systematic review shows that the disk diffusion method could be a real alternative for triazole antifungals susceptibility testing of Aspergillus spp.}, keywords = {Agar, Antifungal Agents* / pharmacology, Aspergillus, doi:10.1016/j.mycmed.2023.101413, Isidore W Yerbanga, Itraconazole* / pharmacology, MEDLINE, Microbial Sensitivity Tests, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, pmid:37603962, PubMed Abstract, Reproducibility of Results, Review, Sanata Bamba, Seydou Nakanabo Diallo, Systematic review, Triazoles / pharmacology, Voriconazole / pharmacology}, pubstate = {published}, tppubtype = {article} } Close The therapeutic management of invasive aspergillosis should be guided by antifungal susceptibility testing (AFST). The disk diffusion (DD) method due to its simplicity and low cost could be an appropriate alternative to the reference methods (CLSI, EUCAST) which are not suitable for AFST in routine clinical microbiology laboratories, particularly in resource-constrained settings. This review summarizes the available data on the performance of the DD method in determining triazole susceptibility profile of Aspergillus species. The published articles on the performance of DD method for determining triazole susceptibility of Aspergillus spp. were systematically searched on major medical databases and Google Scholar. We identified 2725 articles of which 13 met the inclusion criteria. The overall average agreement value obtained between DD and CLSI broth microdilution (CLSI-BMD) methods for the itraconazole 10 µg disk (70.75%) was low especially when the medium used was not Mueller-Hinton (MH) agar. In contrast average agreement for the voriconazole 1 µg disk and the posaconazole 5 µg disk were > 94% regardless of media used. The correlation coefficient values between the DD and CLSI-BMD methods on MH agar were acceptable (≥ 0.71) for the itraconazole 10 µg disk and posaconazole 5 µg disk and good (≥ 0.80) for the voriconazole 1 and 10 µg disk. The reproducibility of the DD method regardless to the medium used was ≥ 82%. This systematic review shows that the disk diffusion method could be a real alternative for triazole antifungals susceptibility testing of Aspergillus spp. Close
2021
Journal Articles
	Serge Ouoba, Jean Claude Romaric Pingdwinde Ouedraogo, Moussa Lingani, Bunthen E, Md Razeen Ashraf Hussain, Ko Ko, Shintaro Nagashima, Aya Sugiyama, Tomoyuki Akita, Halidou Tinto, Junko Tanaka Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis Journal Article In: BMC Infect. Dis., vol. 21, no. 1, pp. 1126, 2021, ISSN: 1471-2334, (© 2021. The Author(s). PMID: 34724902 PMCID: PMC8561994). Abstract \| BibTeX \| Tags: Burkina Faso, Burkina Faso/epidemiology, Genotype, Hepacivirus/genetics, Hepatitis C, Hepatitis C/epidemiology, Humans, Prevalence, Seroepidemiologic Studies, Seroprevalence, Systematic review \| Links: Close Close @article{Ouoba2021-ug, title = {Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis}, author = {Serge Ouoba and Jean Claude Romaric Pingdwinde Ouedraogo and Moussa Lingani and Bunthen E and Md Razeen Ashraf Hussain and Ko Ko and Shintaro Nagashima and Aya Sugiyama and Tomoyuki Akita and Halidou Tinto and Junko Tanaka}, doi = {10.1186/s12879-021-06817-x}, issn = {1471-2334}, year = {2021}, date = {2021-11-01}, urldate = {2021-11-01}, journal = {BMC Infect. Dis.}, volume = {21}, number = {1}, pages = {1126}, publisher = {Springer Science and Business Media LLC}, abstract = {BACKGROUND: Detailed characteristics of Hepatitis C virus (HCV) infection in Burkina Faso are scarce. The main aim of this study was to assess HCV seroprevalence in various settings and populations at risk in Burkina Faso between 1990 and 2020. Secondary objectives included the prevalence of HCV Ribonucleic acid (RNA) and the distribution of HCV genotypes. METHODS: A systematic database search, supplemented by a manual search, was conducted in PubMed, Web of Science, Scopus, and African Index Medicus. Studies reporting HCV seroprevalence data in low and high-risk populations in Burkina Faso were included, and a random-effects meta-analysis was applied. Risk of bias was assessed using the Joanna Briggs institute checklist. RESULTS: Low-risk populations were examined in 31 studies involving a total of 168,151 subjects, of whom 8330 were positive for HCV antibodies. Six studies included a total of 1484 high-risk persons, and 96 had antibodies to HCV. The pooled seroprevalence in low-risk populations was 3.72% (95% CI: 3.20-4.28) and 4.75% (95% CI: 1.79-8.94) in high-risk groups. A non-significant decreasing trend was observed over the study period. Seven studies tested HCV RNA in a total of 4759 individuals at low risk for HCV infection, and 81 were positive. The meta-analysis of HCV RNA yielded a pooled prevalence of 1.65% (95% CI: 0.74-2.89%) in low-risk populations, which is assumed to be indicative of HCV prevalence in the general population of Burkina Faso and suggests that about 301,174 people are active HCV carriers in the country. Genotypes 2 and 1 were the most frequent, with 60.3% and 25.0%, respectively. CONCLUSIONS: HCV seroprevalence is intermediate in Burkina Faso and indicates the need to implement effective control strategies. There is a paucity of data at the national level and for rural and high-risk populations. General population screening and linkage to care are recommended, with special attention to rural and high-risk populations.}, note = {© 2021. The Author(s). PMID: 34724902 PMCID: PMC8561994}, keywords = {Burkina Faso, Burkina Faso/epidemiology, Genotype, Hepacivirus/genetics, Hepatitis C, Hepatitis C/epidemiology, Humans, Prevalence, Seroepidemiologic Studies, Seroprevalence, Systematic review}, pubstate = {published}, tppubtype = {article} } Close BACKGROUND: Detailed characteristics of Hepatitis C virus (HCV) infection in Burkina Faso are scarce. The main aim of this study was to assess HCV seroprevalence in various settings and populations at risk in Burkina Faso between 1990 and 2020. Secondary objectives included the prevalence of HCV Ribonucleic acid (RNA) and the distribution of HCV genotypes. METHODS: A systematic database search, supplemented by a manual search, was conducted in PubMed, Web of Science, Scopus, and African Index Medicus. Studies reporting HCV seroprevalence data in low and high-risk populations in Burkina Faso were included, and a random-effects meta-analysis was applied. Risk of bias was assessed using the Joanna Briggs institute checklist. RESULTS: Low-risk populations were examined in 31 studies involving a total of 168,151 subjects, of whom 8330 were positive for HCV antibodies. Six studies included a total of 1484 high-risk persons, and 96 had antibodies to HCV. The pooled seroprevalence in low-risk populations was 3.72% (95% CI: 3.20-4.28) and 4.75% (95% CI: 1.79-8.94) in high-risk groups. A non-significant decreasing trend was observed over the study period. Seven studies tested HCV RNA in a total of 4759 individuals at low risk for HCV infection, and 81 were positive. The meta-analysis of HCV RNA yielded a pooled prevalence of 1.65% (95% CI: 0.74-2.89%) in low-risk populations, which is assumed to be indicative of HCV prevalence in the general population of Burkina Faso and suggests that about 301,174 people are active HCV carriers in the country. Genotypes 2 and 1 were the most frequent, with 60.3% and 25.0%, respectively. CONCLUSIONS: HCV seroprevalence is intermediate in Burkina Faso and indicates the need to implement effective control strategies. There is a paucity of data at the national level and for rural and high-risk populations. General population screening and linkage to care are recommended, with special attention to rural and high-risk populations. Close